Gain Therapeutics Q3 net loss $4.7M; Phase 1 trial of GT-02287 underway

Gain Therapeutics, Inc.

2023-Q3 EPS reported -$1.42 revenue$55,180

Net loss $4.7M ($0.37/sh) vs $4.6M ($0.38/sh) in Q3 2022; R&D expense rose $0.4M to $2.4M.
Cash, cash equivalents and marketable securities $12.3M; sufficient into Q3 2024.
Phase 1 clinical trial of GT-02287 initiated in Australia; dose escalation ongoing.
Completion of single ascending dose part expected late Q4 2023/early Q1 2024; multiple ascending dose expected Q2 2024.
Preclinical data presented at Parkinson's congress showed GT-02287 reduced NfL biomarker and motor dysfunction.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Gain Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income $4.7 million, or $0.37 per share basic and diluted, EPS $0.37 per share basic and diluted.

Period: third quarter ended September 30, 2023
Net income: $4.7 million, or $0.37 per share basic and diluted
EPS: $0.37 per share basic and diluted
Result: reported results

Exact text from the filing

On November 14, 2023, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, and business update.

View on SEC.gov

Browse all earnings releases →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.